Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 13/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 12/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2549624 | 1.00 | CACNA1H (0.60) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13815513 | 1.00 | CACNA1H (0.60) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14775808 | 0.94 | CACNA1H (0.58) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2546919 | 0.94 | CACNA1H (0.58) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2548169 | 0.94 | CACNA1H (0.58) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14775966 | 0.94 | CACNA1H (0.58) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2543631 | 0.90 | CACNA1H (0.73) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14775891 | 0.90 | CACNA1H (0.73) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2546599 | 0.90 | CACNA1H (0.73) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14775925 | 0.90 | CACNA1H (0.73) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350021-B1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | claimed |
| US-8314253-B2 | Bridged tetrahydronaphthalene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-20 | — | — | US | claimed |
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | claimed |
| EP-2350021-B1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-8314253-B2 | Bridged tetrahydronaphthalene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1E, CACNA1B, CACNB1 | CACNA1H 5/4885CACNA1C 13/4885CYP3A4 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.